SPPL2A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3469437	0.52	10/20
SCHEMBL809775	0.47	8/20
SCHEMBL2133782	0.39	8/20
SCHEMBL2338052	0.60	7/20
SCHEMBL1811018	0.51	7/20
SCHEMBL1057407	0.85	6/20
SCHEMBL1812001	0.83	6/20
SCHEMBL1058746	0.81	6/20
SCHEMBL1056509	0.75	6/20
SCHEMBL2584515	0.48	6/20
SCHEMBL1054108	0.66	5/20
SCHEMBL1057302	0.66	5/20
SCHEMBL2532216	0.53	5/20
SCHEMBL1055917	0.73	4/20
SCHEMBL1056520	0.73	4/20
SCHEMBL1058776	0.73	4/20
Water (SCHEMBL1058138)	0.71	4/20
SCHEMBL1059472	0.70	4/20
SCHEMBL1058448	0.69	4/20
SCHEMBL1059008	0.67	4/20

Clinical trials — most relevant to SPPL2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Sitagliptin and Endothelial Dysfunction	PHASE3	UNKNOWN
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers	PHASE2	COMPLETED
Pappalysin 2 (PAPP-A2) Enzyme Replacement	PHASE1	COMPLETED
PTHrP(1-36) IV Dose Escalation Study	PHASE1	WITHDRAWN
Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI	EARLY_PHASE1	RECRUITING
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism	EARLY_PHASE1	UNKNOWN
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS	nan	COMPLETED
Urine and Serum Concentrations of Pregnancy-Associated Compounds During Gestation	nan	COMPLETED
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application	nan	COMPLETED
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism	nan	UNKNOWN
Analysis by Clinical Mass Spectrometry of Bloodstains	nan	COMPLETED
Surfactant Derived Protocol in Heart Failure	nan	COMPLETED
Biomarkers of Lichen Sclerosus	nan	UNKNOWN
Diagnostic and Prognostic Role of Troponin and Brain Natriuretic Peptide in Pediatric Patients With Cardiomyopathy in Correlation to Echocardiography Findings	nan	UNKNOWN
The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism	nan	UNKNOWN
Impact of Seasonal Malaria Chemoprevention on Immunity Against Malaria Among Children in Northern Benin	nan	COMPLETED
Proteomic Study of Urinary Stone Disease	nan	COMPLETED
The Recurrence Study	nan	UNKNOWN
Efficacy Study of Rapid Immunoassay Diagnostic Test Utilizing PP12 and AFP, ROM Plus	nan	UNKNOWN
Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects)	nan	UNKNOWN
TMJ Arthroscopic Lysis and Lavage Compared to Operative Arthroscopy in Disc Displacement With Reduction.	nan	RECRUITING
Novel Biomarkers of Preeclampsia, Aquaporin, Fatty Acid, and S110B	nan	COMPLETED
Age, Lifestyle, Muscle Mechanisms in Insulin Resistance	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Identification of Biomarkers for Early Detection of Pancreatic Cancer	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients	nan	COMPLETED
Identification and Characterization of the Biomarker in Synovial Fluid for Hyaluronic Acid Therapy in Osteoarthritis	nan	COMPLETED
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SPPL2A binder may also engage these)

Protein	Name	Similarity
Q9JJF9	—	0.993	Q9JJF9 →
Q3TD49	—	0.985	Q3TD49 →
Q5PQL3	—	0.980	Q5PQL3 →
Q5F383	—	0.976	Q5F383 →
Q53P98	—	0.972	Q53P98 →
Q4V3B8	—	0.971	Q4V3B8 →
Q7G7C7	—	0.966	Q7G7C7 →
A7MBC7	—	0.963	A7MBC7 →
Q6ZQE4	—	0.963	Q6ZQE4 →
Q8TCT6	—	0.961	Q8TCT6 →
O14524	—	0.960	O14524 →
Q52KP5	—	0.960	Q52KP5 →
D3ZWZ9	—	0.960	D3ZWZ9 →
Q9CUS9	—	0.960	Q9CUS9 →
X1WEM4	—	0.960	X1WEM4 →
Q5RDB4	—	0.960	Q5RDB4 →
Q9NXL6	—	0.959	Q9NXL6 →
Q921R8	—	0.959	Q921R8 →
Q6AXF6	—	0.958	Q6AXF6 →
Q687X5	—	0.958	Q687X5 →
TRPM6	Transient receptor potential cation channel subfamily M member 6	0.958	landscape →
Q9MA44	—	0.957	Q9MA44 →
Q8BUV8	—	0.956	Q8BUV8 →
S5UH55	—	0.956	S5UH55 →
Q8C428	—	0.956	Q8C428 →
Q5YCC5	—	0.956	Q5YCC5 →
Q05004	—	0.956	Q05004 →
Q6GQE1	—	0.955	Q6GQE1 →
Q60457	—	0.955	Q60457 →
P98192	—	0.955	P98192 →